Table 1.

The association of rs700635 and rs1035142 with prostate cancer

Sample Set	Number of cases	Number of controls	rs700635[C]					rs1035142[T]
			Frequency in controls	OR	95%CI	P	Pheta	Frequency in controls	OR	95%CI	P	Pheta
Icelandb	5274	97 905	0.299	0.92	(0.87–0.97)	0.0018		0.379	0.93	(0.89–0.98)	0.0064
Netherlands	1445	3746	0.288	0.84	(0.76–0.92)	3.0 × 10−4		0.399	0.83	(0.76–0.91)	3.6 × 10−5
Spain	729	1923	0.288	0.85	(0.74–0.98)	0.021		0.413	0.94	(0.83–1.06)	0.32
UK	543	1889	0.263	0.84	(0.72–0.98)	0.030		0.364	0.81	(0.70–0.93)	0.0038
USA	1547	1291	0.277	1.03	(0.92–1.16)	0.610		0.393	0.97	(0.87–1.08)	0.54
Romania	981	1122	0.286	0.95	(0.83–1.09)	0.480		0.442	0.94	(0.83–1.06)	0.30
All non-Icelandicc	5245	9971		0.90	(0.85–0.94)	1.4 × 10−4	0.053		0.89	(0.85–0.94)	7.4 × 10−6	0.10
All combinedd	10 519	107 876		0.91	(0.88–0.95)	1.0 × 10−6e	0.083		0.91	(0.88–0.95)	3.8 × 10−7f	0.091

^aLikelihood ratio test for heterogeneity.

^bEstimated effective sample size 8237 cases and 8237 controls, after adjusting for genomic control.

^cEstimated effective sample size 6441 cases and 6441 controls.

^dEstimated effective sample size 14 678 cases and 14 678 controls, after adjusting for genomic control.

^eP_adj conditioned on rs1035142 = 0.18.

^fP_adj conditioned on rs700635 = 0.044.